Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors

19 Feb 2020

Abstract excerpt

In this study, a drug discovery programme that sought to identify novel dual bacterial topoisomerase II inhibitors (NBTIs) led to the selection of six optimized compounds. In enzymatic assays, the molecules showed equivalent dual-targeting activity against the DNA gyrase and topoisomerase IV enzymes of Staphylococcus aureus and Escherichia coli. Consistently, the compounds demonstrated potent activity in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Cancer therapeutics and mechanisms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32074119
DOI: 10.1371/journal.pone.0228509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitorsPMID 32074119Read ↗

Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. HydeSemantic proximity Read ↗

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial AgentsSemantic proximity Read ↗

Inhibitors of Bacterial Topoisomerases: Mechanisms of Action and Resistance and Clinical Aspects1Semantic proximity Read ↗

Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.Semantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA GyraseSemantic proximity Read ↗

Rational design of balanced dual-targeting antibiotics with limited resistance.Semantic proximity Read ↗

In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.Semantic proximity Read ↗

Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Semantic proximity Read ↗

Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.Semantic proximity Read ↗

Novel Tetrazole-Based Antimicrobial Agents Targeting Clinical Bacteria Strains: Exploring the Inhibition of Staphylococcus aureus DNA Topoisomerase IV and GyraseSemantic proximity Read ↗

Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.Semantic proximity Read ↗

Mechanism of action of and resistance to quinolones.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.